156 related articles for article (PubMed ID: 38035973)
21. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
22. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
23. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
24. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
25. Opposite effects of N,N-dimethyltryptamine (DMT) and 5-methoxy-n,n-dimethyltryptamine (5-MeODMT) on acoustic startle: spinal vs brain sites of action.
Commissaris RL; Davis M
Neurosci Biobehav Rev; 1982; 6(4):515-20. PubMed ID: 6817240
[TBL] [Abstract][Full Text] [Related]
26. Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.
Kalirajan R; Rishabh K; Srikanth J; Niharika M; Preeya N; Rezaul I
Arch Razi Inst; 2023 Oct; 78(5):1603-1614. PubMed ID: 38590677
[TBL] [Abstract][Full Text] [Related]
27. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
28. A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus.
Helsley S; Fiorella D; Rabin RA; Winter JC
Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):649-63. PubMed ID: 9682278
[TBL] [Abstract][Full Text] [Related]
29. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Halberstadt AL; Nichols DE; Geyer MA
Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
31. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
32. Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices.
Gaujac A; Navickiene S; Collins MI; Brandt SD; de Andrade JB
Drug Test Anal; 2012; 4(7-8):636-48. PubMed ID: 22577086
[TBL] [Abstract][Full Text] [Related]
33. Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methythio counterparts.
Glennon RA; Young R; Benington F; Morin RD
Life Sci; 1982 Feb; 30(5):465-7. PubMed ID: 6801410
[TBL] [Abstract][Full Text] [Related]
34. Plants and mushrooms of abuse.
Spoerke DG; Hall AH
Emerg Med Clin North Am; 1990 Aug; 8(3):579-93. PubMed ID: 2201522
[TBL] [Abstract][Full Text] [Related]
35. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia.
Pomilio AB; Vitale AA; Ciprian-Ollivier J; Cetkovich-Bakmas M; Gómez R; Vázquez G
J Ethnopharmacol; 1999 Apr; 65(1):29-51. PubMed ID: 10350367
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the synthesis of N,N-dimethyltryptamine by reductive amination using gas chromatography ion trap mass spectrometry.
Brandt SD; Moore SA; Freeman S; Kanu AB
Drug Test Anal; 2010 Jul; 2(7):330-8. PubMed ID: 20648523
[TBL] [Abstract][Full Text] [Related]
37. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity.
Adams LM; Geyer MA
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(2):121-32. PubMed ID: 3858911
[TBL] [Abstract][Full Text] [Related]
38. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca.
Yritia M; Riba J; Ortuño J; Ramirez A; Castillo A; Alfaro Y; de la Torre R; Barbanoj MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 779(2):271-81. PubMed ID: 12361741
[TBL] [Abstract][Full Text] [Related]
39. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
Smith RL; Canton H; Barrett RJ; Sanders-Bush E
Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
[TBL] [Abstract][Full Text] [Related]
40. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
Kärkkäinen J; Forsström T; Tornaeus J; Wähälä K; Kiuru P; Honkanen A; Stenman UH; Turpeinen U; Hesso A
Scand J Clin Lab Invest; 2005; 65(3):189-99. PubMed ID: 16095048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
